Welcome!
Pharmesis International
Healthcare
Pharmesis International’s subsidiary to acquire 19% interest in Sichuan Longlife Pharmaceutical
The purchase consideration for the proposed acquisition stands at RMB2,830,000, to be paid in two instalments.
September 23, 2024
Results
Pharmesis International narrows 3Q losses by 29% to $40,600
SINGAPORE (Nov 9): Pharmesis International reported 3Q17 losses narrowed by 29% to RMB 198,000 ($40,600) compared to RMB 279,000 in 3Q16.
November 09, 2017